AIMC Topic: Paroxetine

Clear Filters Showing 1 to 4 of 4 articles

Cingulate atrophy as a shared structural basis for cognitive and functional brain impairments in GAD, PD, and OCD: Links to shared gene expression and treatment implications.

Journal of affective disorders
BACKGROUND: Structural brain deficits associated with generalized anxiety disorder (GAD), panic disorder (PD), and obsessive-compulsive disorder (OCD) have been documented, but their integration within a unified framework remains unexplored. This stu...

Influence of panic disorder and paroxetine on brain functional hubs in drug-free patients.

Journal of psychopharmacology (Oxford, England)
BACKGROUND: The effects of panic disorder (PD) and pharmacotherapy on brain functional hubs in drug-free patients, and the utility of their degree centrality (DC) in diagnosing and predicting treatment response (TR) for PD, remained unclear.

High-throughput liquid chromatography tandem mass spectrometry method for simultaneous determination of fampridine, paroxetine, and quinidine in rat plasma: Application to in vivo perfusion study.

Journal of food and drug analysis
A selective and high-throughput liquid chromatography-mass spectrometry method has been developed and validated for the simultaneous quantification of paroxetine, fampridine, and quinidine in rat plasma using imipramine as an internal standard. Follo...

Effect of Cumulative Exposure on the Efficacy of Paroxetine: A Population Pharmacokinetic-Pharmacodynamic and Machine Learning Analyses.

CPT: pharmacometrics & systems pharmacology
Selective serotonin reuptake inhibitors (SSRIs) are widely used in depression treatment. However, the relationship between treatment efficacy and plasma concentrations remains unclear. We assessed whether the anti-depressive response can be predicted...